Xentuzumab

Generic Name: Xentuzumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1417158-65-6

Unique Ingredient Identifier: X86Z1O656G

Background: Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN)

Early Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Xentuzumab

First Posted Date: 2021-11-08

Last Posted Date: 2023-04-21

Lead Sponsor: University of Oxford

Target Recruit Count: 27

Registration Number: NCT05110495

Locations: 🇬🇧
Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Placebo
Drug: Xentuzumab
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2018-09-06

Last Posted Date: 2024-07-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT03659136

Locations: 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸
Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States

and more 51 locations

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1

Completed

Conditions: Neoplasms
Breast Neoplasms

Interventions: Drug: Xentuzumab
Drug: Abemaciclib
Drug: Letrozole
Drug: Anastrozole
Drug: Fulvestrant

First Posted Date: 2017-04-04

Last Posted Date: 2024-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 133

Registration Number: NCT03099174

Locations: 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 27 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy